This report describes and explains the point of care hematology diagnostics market and covers 2020-2025, termed the historic period, and 2025-2030, 2035F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.
The global point of care hematology diagnostics market reached a value of nearly $2.9 billion in 2025, having grown at a compound annual growth rate (CAGR) of 8.3% since 2020. The market is expected to grow from $2.9 billion in 2025 to $4.26 billion in 2030 at a rate of 8%. The market is then expected to grow at a CAGR of 7% from 2030 and reach $5.97 billion in 2035.
Growth in the historic period resulted from growing awareness and screening programs for anemia and blood-related conditions, rising prevalence of infectious diseases increasing investment in healthcare infrastructure and diagnostics, and growing prevalence of chronic blood disorders. Factors that negatively affected growth in the historic period were limited high cost of devices and supply chain disruptions.
Going forward, rising geriatric population, increasing use of point of care diagnostics in rural and remote healthcare settings and increasing demand for cost-effective diagnostic tools, and expansion of private diagnostic centers and clinic chains will drive the growth. Factors that could hinder the growth of the point of care hematology diagnostics market in the future include regulatory challenges, connectivity issues and impact of trade war and tariff.
Market trends for the point of care hematology diagnostics market include AI-powered portable systems revolutionize rapid blood analysis for faster clinical decisions, advancements in compact in-clinic hematology analyzers for rapid and decentralized blood testing, integration of multimodal benchtop analyzers enabling rapid decentralized blood testing and faster clinical decision-making, advancements in AI-enabled cartridge-based blood analysis for rapid and accurate on-site diagnostics and next-generation low-volume blood testing transforming diagnostics.
The point of care hematology diagnostics market is segmented by type into complete blood count, coagulation testing, hemoglobin testing, anemia diagnosis and other types. The complete blood count market was the largest segment of the point of care hematology diagnostics market segmented by type, accounting for 42% or $1.21 billion of the total in 2025. Going forward, the hemoglobin testing segment is expected to be the fastest-growing segment in the point of care hematology diagnostics market segmented by type, at a CAGR of 8.1% during 2025-2030.
The point of care hematology diagnostics market is segmented by mode of prescription into prescription based product and over-the-counter based product. The prescription based product was the largest segment of the point of care hematology diagnostics market segmented by mode of prescription, accounting for 79.2% or $2.29 billion of the total in 2025. Going forward, the over-the-counter based product segment is expected to be the fastest-growing segment in the point of care hematology diagnostics market segmented by mode of prescription, at a CAGR of 10% during 2025-2030.
The point of care hematology diagnostics market is segmented by end user into diagnostic centers, hospitals, blood banks, transfusion centers and other end users. The hospitals market was the largest segment of the point of care hematology diagnostics market segmented by end user, accounting for 41.6% or $1.2 billion of the total in 2025. Going forward, the diagnostic centers segment is expected to be the fastest-growing segment in the point of care hematology diagnostics market segmented by end user, at a CAGR of 9% during 2025-2030.
North America was the largest region in the point of care hematology diagnostics market, accounting for 33.7% or $976.4 million of the total in 2025. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the point of care hematology diagnostics market will be Asia Pacific and South America where growth will be at CAGRs of 10% and 8.8% respectively. These will be followed by Eastern Europe and Middle East where the markets are expected to grow at CAGRs of 8.3% and 8% respectively.
The global point of care hematology diagnostics market is fairly fragmented, with a large number of small players operating in the market. The top 10 competitors in the market made up 24.27% of the total market in 2024. Cigna Corp. was the largest competitor with a 3.84% share of the market, followed by Bupa Global Limited with 3.26%, AXA S.A. with 3.04%, Allianz Group, with 2.98%, GeoBlue LLC (Blue Cross Blue Shield Global Solutions), with 2.97%, UnitedHealth Group Incorporated with 2.78%, Generali Global Health with 1.60%, Tokio Marine Holdings Inc. with 1.43%, MAPFRE with 1.23% and Aetna International Inc. with 1.14%.
The top opportunities in the point of care hematology diagnostics market segmented by type will arise in the complete blood count segment, which will gain $529.1 million of global annual sales by 2030. The top opportunities in the point of care hematology diagnostics market segmented by mode of prescription will arise in the prescription based product segment, which will gain $992.7 million of global annual sales by 2030. The top opportunities in the point of care hematology diagnostics market segmented by end user will arise in the diagnostic centers segment, which will gain $520.3 million of global annual sales by 2030. The point of care hematology diagnostics market size will gain the most in the USA at $305.5 million.
Player-adopted strategies in the point of care hematology diagnostics market include focus on strengthening its operational capabilities through new facility investments and new launches.
Market-trend-based strategies for the point of care hematology diagnostics market include focus on technologically advanced solutions, such as AI-powered portable blood analysis systems, to enable rapid, accurate, and decentralized testing for improved clinical decision-making and patient outcomes, developing innovative solutions, such as compact in-clinic hematology analyzers, to meet the rising demand for rapid, accurate, and decentralized blood testing in clinical and veterinary settings, developing innovative solutions, such as multimodal blood testing benchtop analyzers, reducing reliance on centralized laboratories, concentrating on advanced innovations, such as cartridge-based AI-enabled hematology analyzers and developing innovative solutions, such as microfluidics-based hematology devices, to deliver fast, low-volume, and cost-effective blood analysis in decentralized healthcare settings.
To take advantage of the opportunities, the analyst recommends the point of care hematology diagnostics companies to focus on AI-enabled portable diagnostics for rapid point-of-care decision making, focus on compact in-clinic hematology analyzers for decentralized testing efficiency, focus on multimodal benchtop analyzers for integrated point-of-care diagnostics, focus on AI-enabled cartridge-based hematology systems for rapid on-site testing, focus on microfluidics-based low-volume diagnostics for decentralized care expansion, focus on coagulation testing for high-growth point-of-care expansion, focus on over-the-counter diagnostics for consumer-led market expansion, focus on multi-channel distribution across decentralized care settings, focus on tiered value-based pricing across care settings, focus on clinical value communication to drive institutional adoption, focus on digital and direct engagement to expand market reach, focus on diagnostic centers for high-growth decentralized testing.
This product will be delivered within 3-5 business days.
The global point of care hematology diagnostics market reached a value of nearly $2.9 billion in 2025, having grown at a compound annual growth rate (CAGR) of 8.3% since 2020. The market is expected to grow from $2.9 billion in 2025 to $4.26 billion in 2030 at a rate of 8%. The market is then expected to grow at a CAGR of 7% from 2030 and reach $5.97 billion in 2035.
Growth in the historic period resulted from growing awareness and screening programs for anemia and blood-related conditions, rising prevalence of infectious diseases increasing investment in healthcare infrastructure and diagnostics, and growing prevalence of chronic blood disorders. Factors that negatively affected growth in the historic period were limited high cost of devices and supply chain disruptions.
Going forward, rising geriatric population, increasing use of point of care diagnostics in rural and remote healthcare settings and increasing demand for cost-effective diagnostic tools, and expansion of private diagnostic centers and clinic chains will drive the growth. Factors that could hinder the growth of the point of care hematology diagnostics market in the future include regulatory challenges, connectivity issues and impact of trade war and tariff.
Market trends for the point of care hematology diagnostics market include AI-powered portable systems revolutionize rapid blood analysis for faster clinical decisions, advancements in compact in-clinic hematology analyzers for rapid and decentralized blood testing, integration of multimodal benchtop analyzers enabling rapid decentralized blood testing and faster clinical decision-making, advancements in AI-enabled cartridge-based blood analysis for rapid and accurate on-site diagnostics and next-generation low-volume blood testing transforming diagnostics.
The point of care hematology diagnostics market is segmented by type into complete blood count, coagulation testing, hemoglobin testing, anemia diagnosis and other types. The complete blood count market was the largest segment of the point of care hematology diagnostics market segmented by type, accounting for 42% or $1.21 billion of the total in 2025. Going forward, the hemoglobin testing segment is expected to be the fastest-growing segment in the point of care hematology diagnostics market segmented by type, at a CAGR of 8.1% during 2025-2030.
The point of care hematology diagnostics market is segmented by mode of prescription into prescription based product and over-the-counter based product. The prescription based product was the largest segment of the point of care hematology diagnostics market segmented by mode of prescription, accounting for 79.2% or $2.29 billion of the total in 2025. Going forward, the over-the-counter based product segment is expected to be the fastest-growing segment in the point of care hematology diagnostics market segmented by mode of prescription, at a CAGR of 10% during 2025-2030.
The point of care hematology diagnostics market is segmented by end user into diagnostic centers, hospitals, blood banks, transfusion centers and other end users. The hospitals market was the largest segment of the point of care hematology diagnostics market segmented by end user, accounting for 41.6% or $1.2 billion of the total in 2025. Going forward, the diagnostic centers segment is expected to be the fastest-growing segment in the point of care hematology diagnostics market segmented by end user, at a CAGR of 9% during 2025-2030.
North America was the largest region in the point of care hematology diagnostics market, accounting for 33.7% or $976.4 million of the total in 2025. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the point of care hematology diagnostics market will be Asia Pacific and South America where growth will be at CAGRs of 10% and 8.8% respectively. These will be followed by Eastern Europe and Middle East where the markets are expected to grow at CAGRs of 8.3% and 8% respectively.
The global point of care hematology diagnostics market is fairly fragmented, with a large number of small players operating in the market. The top 10 competitors in the market made up 24.27% of the total market in 2024. Cigna Corp. was the largest competitor with a 3.84% share of the market, followed by Bupa Global Limited with 3.26%, AXA S.A. with 3.04%, Allianz Group, with 2.98%, GeoBlue LLC (Blue Cross Blue Shield Global Solutions), with 2.97%, UnitedHealth Group Incorporated with 2.78%, Generali Global Health with 1.60%, Tokio Marine Holdings Inc. with 1.43%, MAPFRE with 1.23% and Aetna International Inc. with 1.14%.
The top opportunities in the point of care hematology diagnostics market segmented by type will arise in the complete blood count segment, which will gain $529.1 million of global annual sales by 2030. The top opportunities in the point of care hematology diagnostics market segmented by mode of prescription will arise in the prescription based product segment, which will gain $992.7 million of global annual sales by 2030. The top opportunities in the point of care hematology diagnostics market segmented by end user will arise in the diagnostic centers segment, which will gain $520.3 million of global annual sales by 2030. The point of care hematology diagnostics market size will gain the most in the USA at $305.5 million.
Player-adopted strategies in the point of care hematology diagnostics market include focus on strengthening its operational capabilities through new facility investments and new launches.
Market-trend-based strategies for the point of care hematology diagnostics market include focus on technologically advanced solutions, such as AI-powered portable blood analysis systems, to enable rapid, accurate, and decentralized testing for improved clinical decision-making and patient outcomes, developing innovative solutions, such as compact in-clinic hematology analyzers, to meet the rising demand for rapid, accurate, and decentralized blood testing in clinical and veterinary settings, developing innovative solutions, such as multimodal blood testing benchtop analyzers, reducing reliance on centralized laboratories, concentrating on advanced innovations, such as cartridge-based AI-enabled hematology analyzers and developing innovative solutions, such as microfluidics-based hematology devices, to deliver fast, low-volume, and cost-effective blood analysis in decentralized healthcare settings.
To take advantage of the opportunities, the analyst recommends the point of care hematology diagnostics companies to focus on AI-enabled portable diagnostics for rapid point-of-care decision making, focus on compact in-clinic hematology analyzers for decentralized testing efficiency, focus on multimodal benchtop analyzers for integrated point-of-care diagnostics, focus on AI-enabled cartridge-based hematology systems for rapid on-site testing, focus on microfluidics-based low-volume diagnostics for decentralized care expansion, focus on coagulation testing for high-growth point-of-care expansion, focus on over-the-counter diagnostics for consumer-led market expansion, focus on multi-channel distribution across decentralized care settings, focus on tiered value-based pricing across care settings, focus on clinical value communication to drive institutional adoption, focus on digital and direct engagement to expand market reach, focus on diagnostic centers for high-growth decentralized testing.
This product will be delivered within 3-5 business days.
Table of Contents
1 Executive Summary
6 Market Characteristics
7 Point Of Care Hematology Diagnostics Market, Overview Of Key Products/Services
8 Point Of Care Hematology Diagnostics Market, Supply Chain Analysis
9 Major Market Trends
10 Point Of Care Hematology Diagnostics Growth Analysis And Strategic Analysis Framework
11 Global Point Of Care Hematology Diagnostics Market Size And Growth Analysis
12 Global Point Of Care Hematology Diagnostics Total Addressable Market (TAM) Analysis
13 Global Point Of Care Hematology Diagnostics Market Segmentation
14 Point Of Care Hematology Diagnostics Market, Regional and Country Analysis
15 Asia-Pacific Market
16 South East Asia Market
17 Western Europe Market
18 Eastern Europe Market
19 North America Market
20 South America Market
21 Middle East Market
22 Africa Market
23 Competitive Landscape And Company Profiles
24 Other Major And Innovative Companies
27 Point Of Care Hematology Diagnostics Market - Company Scoring Matrix
29 Key Mergers And Acquisitions
30 Recent Developments
31 Opportunities And Strategies
32 Point Of Care Hematology Diagnostics Market, Conclusions And Recommendations
33 Appendix
Executive Summary
Point Of Care Hematology Diagnostics Global Market Opportunities And Strategies To 2035 provides the strategists; marketers and senior management with the critical information they need to assess the global point of care hematology diagnostics market as it emerges from the COVID-19 shut down.Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description
Where is the largest and fastest-growing market for point of care hematology diagnostics? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The point of care hematology diagnostics market global report answers all these questions and many more.The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider point of care hematology diagnostics market; and compares it with other markets.
The report covers the following chapters:
- Introduction and Market Characteristics - Brief introduction to the segmentations covered in the market, definitions and explanations about the segments, key products, supply chain and market attractiveness scoring and analysis.
- Key Trends - Highlights the major trends shaping the global market. This section also highlights likely future developments in the market
- Growth Analysis And Strategic Analysis Framework Analysis on PESTEL, end use industries, market growth rate, global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods, forecast growth contributors and total addressable market (TAM).
- Global Market Size And Growth Global historic (2020-2025) and forecast (2025-2030, 2035F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional And Country Analysis - Historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison by region and country.
- Market Segmentation - Contains the market values (2020-2025) (2025-2030, 2035F) and analysis for each segment by type into, by mode of prescription, by end user channel in the market. Historic (2020-2025) and forecast (2025-2030) and (2030-2035) market values and growth and market share comparison by region market.
- Regional Market Size and Growth - Regional market size (2025), historic (2020-2025) and forecast (2025-2030, 2035F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape - Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major And Innovative Companies Details on the company profiles of other major and innovative companies in the market.
- Competitive Benchmarking - Briefs on the financials comparison between major players in the market.
- Competitive Dashboard - Briefs on competitive dashboard of major players.
- Key Mergers and Acquisitions - Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Recent Developments Information on recent developments in the market covered in the report.
- Market Opportunities And Strategies - Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions And Recommendations - This section includes recommendations for point of care hematology diagnostics providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
1) By Type Into: Complete Blood Count; Coagulation Testing; Hemoglobin Testing; Anemia Diagnosis; Other Types
2) By Mode Of Prescription: Prescription-Based Product; Over-The-Counter Based Product.
3) By End User: Diagnostic Centers; Hospitals; Blood Banks; Transfusion Centers; Other End Users
Companies Mentioned: Danaher Corporation (HemoCue AB); F. Hoffmann-La Roche Ltd.; Abbott Laboratories; Siemens Healthineers; Sysmex Corporation
Countries: China; Germany; Japan; UK; France; India; USA; Canada; South Korea; Brazil; Australia; Russia; Spain; Italy; Indonesia; Taiwan
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; point of care hematology diagnostics indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Companies Mentioned
- Danaher Corporation (HemoCue AB)
- F. Hoffmann-La Roche Ltd.
- Abbott Laboratories
- Siemens Healthineers
- Sysmex Corporation
- Shenzhen Mindray Bio-Medical Electronics Co. Ltd.
- Instrumentation Laboratory (Werfen)
- Nova Biomedical Corp.
- Chengdu Seamaty Technology Co. Ltd.
- Edan Instruments Inc.
- Mindray Medical International Limited
- Trivitron Healthcare
- PixCell Medical
- Noul Co., Ltd.
- EKF Diagnostics
- SigTuple
- Sysmex Corporation
- EKF Diagnostics Holdings
- PixCell Medical Technologies
- F. Hoffmann-La Roche Ltd.
- ERBA Mannheim
- Siemens Healthineers
- DIAGON Kft.
- Boule Diagnostics AB
- HORIBA Medical
- EKF Diagnostics Holdings plc
- Norma Instruments Zrt.
- Sight Diagnostics Inc.
- Sysmex Canada Inc.
- Truvian Health
- Athelas
- Shenzhen Mindray Bio-Medical
- HORIBA Ltd.
- Hilab
- PixCell Medical Technologies Ltd.
- Sight Diagnostics Ltd.
- HemoCue AB
